We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-25.41%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$253M
AUM Growth
-$3.7M
Cap. Flow
+$136M
Cap. Flow %
53.73%
Top 10 Hldgs %
59.38%
Holding
46
New
12
Increased
10
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$41.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16.4M
4
RLYP
RELYPSA INC COM
RLYP
+$14.5M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.8M

Top Sells

Rank Stock Value
1
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$6.77M
2
ASND icon
Ascendis Pharma A/S
ASND
+$5.5M
3
ATRS
Antares Pharma, Inc.
ATRS
+$3.49M
4
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$3.45M
5
XNPT
XENOPORT, INC.
XNPT
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 54%
2 Technology 7.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
1
Vanda Pharmaceuticals
VNDA
$307M
$19.3M 7.65%
1,715,000
+301,401
+21% +$3.69M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.9M 7.47%
1,226,785
+548,190
+81% +$11.8M
CNXR
3
DELISTED
Connecture, Inc.
CNXR
$18.8M 7.44%
4,127,232
– –
ADMS
4
DELISTED
Adamas Pharmaceuticals
ADMS
$18.6M 7.35%
1,110,000
+337,400
+44% +$7.68M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$18.4M 7.28%
1,362,763
+1,050,263
+336% +$18.9M
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
$14.3M 5.66%
750,000
+277,261
+59% +$6.62M
RLYP
7
DELISTED
RELYPSA INC COM
RLYP
$14.2M 5.63%
769,047
+529,047
+220% +$14.5M
GWPH
8
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.48M 3.75%
+103,800
New +$11.5M
GWPH
9
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.14M 3.61%
+100,000
New +$11.1M
EXEL icon
10
Exelixis
EXEL
$13.3B
$8.92M 3.53%
+1,590,000
New +$8.65M
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.62M 3.41%
453,878
+38,540
+9% +$960K
TTPH
12
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$8.36M 3.3%
+56,000
New +$41.1M
RPTP
13
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$8.08M 3.19%
+1,335,000
New +$16.4M
ARCT icon
14
Arcturus Therapeutics
ARCT
$164M
$7.28M 2.88%
172,169
+2,300
+1% +$121K
ARDM
15
DELISTED
Aradigm Corp Common Stock
ARDM
$7.22M 2.86%
1,002,962
– –
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$1.91B
$6.92M 2.74%
2,457,144
+516,000
+27% +$1.77M
OCRX
17
DELISTED
Ocera Therapeutics, Inc.
OCRX
$6.21M 2.45%
1,963,777
– –
SGYP
18
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$6.02M 2.38%
1,135,580
-874,404
-44% -$6.77M
MDCO
19
DELISTED
Medicines Co
MDCO
$5.69M 2.25%
+150,000
New +$5.27M
VCEL icon
20
Vericel Corp
VCEL
$2.35B
$5.65M 2.24%
2,086,028
– –
APYX icon
21
Apyx Medical
APYX
$173M
$5.23M 2.07%
2,680,000
– –
STML
22
DELISTED
Stemline Therapeutics, Inc.
STML
$4.2M 1.66%
475,200
– –
ALIM
23
DELISTED
Alimera Sciences
ALIM
$3.72M 1.47%
112,211
– –
LSTA icon
24
Lisata Therapeutics
LSTA
$9.02M
$3.35M 1.33%
14,992
-1,515
-9% -$380K
TENX icon
25
Tenax Therapeutics
TENX
$363M
$3.33M 1.32%
35
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Great Point Partners held 46 positions worth $253M, down 1.4% from $257M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Great Point Partners deployed $136M of net new capital in Q3 2015, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 56,000 shares worth $8.36M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 60% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Synergy Pharmaceuticals, Inc Common Stock, an estimated $6.77M trimmed.

  • Great Point Partners's largest Q3 2015 buy was Tetraphase Pharmaceuticals, Inc.: 56,000 shares worth $8.36M.
  • Great Point Partners added most to Zogenix, Inc. in Q3 2015, an estimated $18.9M increase.
  • Great Point Partners's biggest Q3 2015 reduction was Synergy Pharmaceuticals, Inc Common Stock, cutting an estimated $6.77M.
  • Great Point Partners fully exited Ascendis Pharma A/S in Q3 2015, selling an estimated $5.5M.
  • Great Point Partners's ten largest holdings make up 59% of its $253M portfolio in Q3 2015.
  • Great Point Partners opened 12 new positions and closed 10 in Q3 2015.
  • Great Point Partners's portfolio value fell 1.4% quarter-over-quarter to $253M.

Based on Great Point Partners's 13F filing for Q3 2015, filed 16 Nov 2015.